Apyx Medical Corporation (APYX)
NASDAQ: APYX
· Real-Time Price · USD
2.11
-0.13 (-5.80%)
At close: Jun 27, 2025, 3:26 PM
Apyx Medical Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Advanced Energy Revenue | 38.61M | 43.38M | 36.8M | 42.98M | 22.21M | 22.68M | 13.07M |
| Advanced Energy Revenue Growth | -11.01% | +17.88% | -14.38% | +93.50% | -2.04% | +73.52% | n/a |
| OEM Revenue | 9.5M | 8.97M | 7.71M | 5.53M | 5.5M | 5.56M | 3.62M |
| OEM Revenue Growth | +5.90% | +16.35% | +39.32% | +0.64% | -1.12% | +53.65% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 14.08M | 14M | 13.3M | 15.54M | 8.9M | 8.65M | 3.83K | 5.74M | 32.05M |
| Non-Us Revenue Growth | +0.54% | +5.28% | -14.39% | +74.59% | +2.87% | +225892.69% | -99.93% | -82.10% | n/a |
| United States Revenue | 34.02M | 38.34M | 31.21M | 32.98M | 18.81M | 19.58M | 12.86M | 33.15M | n/a |
| United States Revenue Growth | -11.27% | +22.87% | -5.37% | +75.31% | -3.94% | +52.31% | -61.21% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.38M | 10.89M | 9.45M | 6.93M | 4.9M | 8.59M | 4.84M | 12.01M | 12.06M | 12.92M | 10.48M | 11.82M | 12.93M | 12.9M | 10.85M | 10.49M | 9.49M | 8.84M | 8.05M | 7.29M | 9.5M | 10.43M | 8.78M | 8.05M | 8.11M | 7.35M | 4.7M | 5.73M | 5.29M | 5.02M | 5.12M | 5.65M | 5.25M | 5.2M | 4.63M | 4.62M | 4.65M | 4.24M | 4.46M | 4.18M | 4.5M |
| Selling, General, and Administrative Revenue Growth | -68.96% | +15.33% | +36.24% | +41.60% | -42.99% | +77.44% | -59.68% | -0.46% | -6.63% | +23.30% | -11.35% | -8.60% | +0.28% | +18.87% | +3.39% | +10.57% | +7.40% | +9.78% | +10.47% | -23.27% | -8.93% | +18.79% | +9.06% | -0.79% | +10.32% | +56.34% | -17.88% | +8.24% | +5.36% | -1.86% | -9.45% | +7.58% | +1.08% | +12.39% | +0.15% | -0.65% | +9.57% | -4.87% | +6.60% | -7.04% | n/a |
| Research and Development Revenue | 804K | 1.12M | 1.14M | 1.42M | 1.4M | 1.25M | 1.28M | 1.2M | 1.12M | 1.25M | 1.06M | 1.07M | 1.16M | 947K | 1.18M | 1.08M | 1.11M | 918K | 1.05M | 975K | 980K | 1.1M | 936K | 888K | 810K | 579K | 613K | 816K | 562K | 440K | 610K | 696K | 709K | 676K | 682K | 592K | 668K | 626K | 583K | 505K | 446K |
| Research and Development Revenue Growth | -28.02% | -2.19% | -19.80% | +1.93% | +11.94% | -2.19% | +6.42% | +6.96% | -10.68% | +18.28% | -0.84% | -7.60% | +22.28% | -19.40% | +8.39% | -2.78% | +21.46% | -12.32% | +7.38% | -0.51% | -10.67% | +17.20% | +5.41% | +9.63% | +39.90% | -5.55% | -24.88% | +45.20% | +27.73% | -27.87% | -12.36% | -1.83% | +4.88% | -0.88% | +15.20% | -11.38% | +6.71% | +7.38% | +15.45% | +13.23% | n/a |